Work

Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial

Year: 2017

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: The Lancet Oncology

DOI: 10.1016/s1470-2045(17)30355-8

Authors: Rajen Mody, Arlene Naranjo, Collin Van Ryn, Alice L Yu, Wendy B London, Barry L Shulkin, Marguerite T Parisi, Sabah-E-Noor Servaes, Mitchell B Diccianni, Paul M Sondel, Julia G Bender, John M Maris, Julie R Park, Rochelle Bagatell

Institutions: University of Michigan, C. S. Mott Children's Hospital, University of Florida, Chang Gung University, Chang Gung Memorial Hospital, University of California San Diego, Linkou Chang Gung Memorial Hospital, Harvard University, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, St. Jude Children's Research Hospital, University of Tennessee Health Science Center, Seattle Children's Hospital, University of Washington, Children's Hospital of Philadelphia, University of Pennsylvania, University of Wisconsin–Madison, Columbia University Irving Medical Center, Columbia University

Language: English

Topic: Neuroblastoma Research and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Institutes of Health, National Cancer Institute

Awards: G1475746525, G1504112592, G2901481919, Children's Oncology Group Statistics and Data Center, G997771125

OpenAlex ID: W2618869560

FWCI: 16.43

Cites: 69

Cited by: 277

Related to: 10